Department of Maternal and Child Health and Urological Sciences, "Sapienza" University of Rome, Polyclinic Umberto I, 00161 Rome, Italy.
Int J Mol Sci. 2021 Dec 20;22(24):13650. doi: 10.3390/ijms222413650.
Ovarian cancer (OC) is the second most common cause of death in women with gynecological cancer. Considering the poor prognosis, particularly in the case of platinum-resistant (PtR) disease, a huge effort was made to define new biomarkers able to help physicians in approaching and treating these challenging patients. Currently, most data can be obtained from tumor biopsy samples, but this is not always available and implies a surgical procedure. On the other hand, circulating biomarkers are detected with non-invasive methods, although this might require expensive techniques. Given the fervent hope in their value, here we focused on the most studied circulating biomarkers that could play a role in PtR OC.
卵巢癌 (OC) 是妇科癌症患者死亡的第二大主要原因。鉴于其预后较差，尤其是铂类耐药 (PtR) 疾病的情况下，人们做出了巨大努力来定义新的生物标志物，以帮助医生治疗这些具有挑战性的患者。目前，大多数数据可从肿瘤活检样本中获得，但这并非总是可行，且需要进行手术。另一方面，循环生物标志物可通过非侵入性方法检测，但这可能需要昂贵的技术。鉴于人们对它们的价值寄予厚望，我们在此重点关注最有研究价值的循环生物标志物，它们可能在铂类耐药 OC 中发挥作用。
